ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias

Epigenetics

Volumn 10, Issue 1, 2015, Pages 6-18

  D’Amato, Loredana ^a   Dell’Aversana, Carmela ^b   Conte, Mariarosaria ^a   Ciotta, Alfonso ^a   Scisciola, Lucia ^a   Carissimo, Annamaria ^a   Nebbioso, Angela ^a   Altucci, Lucia ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

Acute myeloid leukemia; Cancer; Differentiation; HDAC inhibitors; Signal transduction

Indexed keywords

ARHGEF3 PROTEIN; CD68 ANTIGEN; ENTINOSTAT; EXOENZYME C3; HISTONE DEACETYLASE INHIBITOR; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ARHGEF3 PROTEIN, HUMAN; HISTONE DEACETYLASE; PROTEIN KINASE INHIBITOR; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PLASMID; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ACUTE MYELOID LEUKEMIA; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM; MONOCYTE MACROPHAGE PRECURSOR CELL; MYELOPOIESIS; PROTEIN TRANSPORT; TUMOR CELL LINE;

CELL LINE, TUMOR; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MONOCYTE-MACROPHAGE PRECURSOR CELLS; MYELOPOIESIS; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84924363616     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/15592294.2014.988035     Document Type: Article

References (61)

1. Conte M, Altucci L. Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances. Clin Cancer Res 2012; 18:5526-34; PMID:22904103; http://dx.doi.org/10.1158/1078-0432.CCR-12-2037
2. Benedetti R, Conte M, Altucci L. Targeting histone deacetylases in diseases: where are we? Antioxid Redox Signal 2014; [Epub ahead of print]; PMID:24382114
3. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325:834-40; PMID:19608861; http://dx.doi.org/10.1126/science.1175371
4. Di Costanzo A, Del Gaudio N, Migliaccio A, Altucci L. Epigenetic drugs against cancer: an evolving landscape. Arch Toxicol 2014; 88:1651-68; PMID:25085708; http://dx.doi.org/10.1007/s00204-014-1315-6
5. Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009; 41:199-213; PMID:18790076; http://dx.doi.org/10.1016/j.biocel.2008.08.020
6. Deplus R, Blanchon L, Rajavelu A, Boukaba A, Defrance M, Luciani J, Rothe F, Dedeurwaerder S, Denis H, Brinkman AB, et al. Regulation of DNA Methylation Patterns by CK2-Mediated Phosphorylation of Dnmt3a. Cell Rep 2014; 8:743-53; PMID:25066127; http://dx.doi.org/10.1016/j.celrep.2014.06.048
7. Ahuja N, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 2014; 124:56-63; PMID:24382390; http://dx.doi.org/10.1172/JCI69736
8. Campbell HS, Hall AE, Sanson-Fisher RW, Barker D, Turner D, Taylor-Brown J. Development and validation of the Short-Form Survivor Unmet Needs Survey (SF-SUNS). Support Care Cancer 2014; 22:1071-9; PMID:24292016; http://dx.doi.org/10.1007/s00520-013-2061-7
9. Treppendahl MB, Kristensen LS, Gronbaek K. Predicting response to epigenetic therapy. J Clin Invest 2014; 124:47-55; PMID:24382389; http://dx.doi.org/10.1172/JCI69737
10. Saeed S, Logie C, Francoijs KJ, Frige G, Romanenghi M, Nielsen FG, Raats L, Shahhoseini M, Huynen M, Altucci L, et al. Chromatin accessibility, p300, and histone acetylation define PML-RARalpha and AML1-ETO binding sites in acute myeloid leukemia. Blood 2012; 120:3058-68; PMID:22923494; http://dx.doi.org/10.1182/blood-2011-10-386086
11. Saeed S, Logie C, Stunnenberg HG, Martens JH. Genome-wide functions of PML-RARalpha in acute promyelocytic leukaemia. Br J Cancer 2011; 104:554-8; PMID:21245861; http://dx.doi.org/10.1038/sj.bjc.6606095
12. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, Altucci L, Stunnenberg HG. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell 2010; 17:173-85; PMID:20159609; http://dx.doi.org/10.1016/j.ccr.2009.12.042
13. De Bellis F, Carafa V, Conte M, Rotili D, Petraglia F, Matarese F, Francoijs KJ, Ablain J, Valente S, Castellano R, et al. Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. Cancer Res 2014; 74:2328-39; PMID:24566867
14. Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J 2014; 4: 170; PMID:24413064
15. Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with’epigenetic’ drugs: an update. Mol Oncol 2012; 6:657-82; PMID:23103179; http://dx.doi.org/10.1016/j.molonc.2012.09.004
16. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 2007; 17:195-211; PMID:17325692
17. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92:1210-6; PMID:10922406; http://dx.doi.org/10.1093/jnci/92.15.1210
18. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev 2002; 16:1587-609; PMID:12101119; http://dx.doi.org/10.1101/gad.1003302
19. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell 2000; 103:227-38; PMID:11057896; http://dx.doi.org/10.1016/S0092-8674(00)00115-X
20. Hall A. G proteins and small GTPases: distant relatives keep in touch. Science 1998; 280:2074-5; PMID:9669963; http://dx.doi.org/10.1126/science.280.5372.2074
21. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005; 21:247-69; PMID:16212495; http://dx.doi.org/10.1146/annurev.cellbio.21.020604.150721
22. Hall A. Rho family GTPases. Biochem Soc Trans 2012; 40:1378-82; PMID:23176484
23. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol 2004; 265:23-32; PMID:14697350; http://dx.doi.org/10.1016/j.ydbio.2003.06.003
24. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420:629-35; PMID:12478284; http://dx.doi.org/10.1038/nature01148
25. Barrio-Real L, Kazanietz MG. Rho GEFs and cancer: linking gene expression and metastatic dissemination. Sci Signal 2012; 5:pe43; PMID:23033535
26. Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood 2010; 115:936-47; PMID:19965643; http://dx.doi.org/10.1182/blood-2009-09-198127
27. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9:690-701; PMID:18719708; http://dx.doi.org/10.1038/nrm2476
28. Garcia-Mata R, Burridge K. Catching a GEF by its tail. Trends Cell Biol 2007; 17:36-43; PMID:17126549; http://dx.doi.org/10.1016/j.tcb.2006.11.004
29. Arthur WT, Ellerbroek SM, Der CJ, Burridge K, Wennerberg K. XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC. J Biol Chem 2002; 277:42964-72; PMID:12221096; http://dx.doi.org/10.1074/jbc.M207401200
30. Serbanovic-Canic J, Cvejic A, Soranzo N, Stemple DL, Ouwehand WH, Freson K. Silencing of RhoA nucleotide exchange factor, ARHGEF3, reveals its unexpected role in iron uptake. Blood 2011; 118:4967-76; PMID:21715309; http://dx.doi.org/10.1182/blood-2011-02-337295
31. Mullin BH, Prince RL, Dick IM, Hart DJ, Spector TD, Dudbridge F, Wilson SG. Identification of a role for the ARHGEF3 gene in postmenopausal osteoporosis. Am J Hum Genet 2008; 82:1262-9; PMID:18499081; http://dx.doi.org/10.1016/j.ajhg.2008.04.016
32. Ling L, Lobie PE. RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription. J Biol Chem 2004; 279:32737-50; PMID:15102857; http://dx.doi.org/10.1074/jbc.M400601200
33. Kurokawa K, Nakamura T, Aoki K, Matsuda M. Mechanism and role of localized activation of Rhofamily GTPases in growth factor-stimulated fibroblasts and neuronal cells. Biochem Soc Trans 2005; 33:631-4; PMID:16042560; http://dx.doi.org/10.1042/BST0330631
34. Kurokawa K, Matsuda M. Localized RhoA activation as a requirement for the induction of membrane ruffling. Mol Biol Cell 2005; 16:4294-303; PMID:15987744; http://dx.doi.org/10.1091/mbc.E04-12-1076
35. Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T, Gutkind JS. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995; 81:1137-46; PMID:7600581; http://dx.doi.org/10.1016/S0092-8674(05)80018-2
36. Minden A, Lin A, Claret FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995; 81:1147-57; PMID:7600582; http://dx.doi.org/10.1016/S0092-8674(05)80019-4
37. Rosso SB, Sussman D, Wynshaw-Boris A, Salinas PC. Wnt signaling through Dishevelled, Rac and JNK regulates dendritic development. Nat Neurosci 2005; 8:34-42; PMID:15608632; http://dx.doi.org/10.1038/nn1374
38. Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, Bokoch GM. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem 1995; 270:23934-6; PMID:7592586; http://dx.doi.org/10.1074/jbc.270.41.23934
39. Kant S, Swat W, Zhang S, Zhang ZY, Neel BG, Flavell RA, Davis RJ. TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev 2011; 25:2069-78; PMID:21979919; http://dx.doi.org/10.1101/gad.17224711
40. Reif K, Cantrell DA. Networking Rho family GTPases in lymphocytes. Immunity 1998; 8:395-401; PMID:9586630; http://dx.doi.org/10.1016/S1074-7613(00)80545-2
41. Karin M. The regulation of AP-1 activity by mitogenactivated protein kinases. J Biol Chem 1995; 270:16483-6; PMID:7622446
42. Deng T, Karin M. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature 1994; 371:171-5; PMID:8072547; http://dx.doi.org/10.1038/371171a0
43. Yu R, Hebbar V, Kim DW, Mandlekar S, Pezzuto JM, Kong AN. Resveratrol inhibits phorbol ester and UVinduced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol Pharmacol 2001; 60:217-24; PMID:11408617
44. Marais R, Wynne J, Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 1993; 73:381-93; PMID:8386592; http://dx.doi.org/10.1016/0092-8674(93)90237-K
45. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995; 269:403-7; PMID:7618106; http://dx.doi.org/10.1126/science.7618106
46. Spencer JA, Misra RP. Expression of the serum response factor gene is regulated by serum response factor binding sites. J Biol Chem 1996; 271:16535-43; PMID:8663310; http://dx.doi.org/10.1074/jbc.271.28.16535
47. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS. The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 2004; 14:29-41; PMID:15068801; http://dx.doi.org/10.1016/S1097-2765(04)00153-4
48. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012; 22:50-5; PMID:22402447; http://dx.doi.org/10.1016/j.gde.2012.02.008
49. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51; PMID:16397526; http://dx.doi.org/10.1038/nrc1779
50. Simo-Riudalbas L, Esteller M. Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol 2014; [Epub ahead of print]; PMID:25039449; http://dx.doi.org/10.1111/bph.12844
51. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-9; PMID:21386836; http://dx.doi.org/10.1038/nm.2305
52. Almouzni G, Altucci L, Amati B, Ashley N, Baulcombe D, Beaujean N, Bock C, Bongcam-Rudloff E, Bousquet J, Braun S, et al. Relationship between genome and epigenome–challenges and requirements for future research. BMC Genomics 2014; 15:487; PMID:24942464; http://dx.doi.org/10.1186/1471-2164-15-487
53. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13 (9):673-91; PMID:25131830; http://dx.doi.org/10.1038/nrd4360
54. Bravo GM, Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia 2014; [Epub ahead of print]; PMID:25142817; http://dx.doi.org/10.1038/leu.2014.244
55. Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget 2014; 5 (16):6558-72; PMID:25115382
56. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181-93; PMID:11902573; http://dx.doi.org/10.1038/35106036
57. Mai A, Jelicic K, Rotili D, Di Noia A, Alfani E, Valente S, Altucci L, Nebbioso A, Massa S, Galanello R, et al. Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol Pharmacol 2007; 72:1111-23; PMID:17666592; http://dx.doi.org/10.1124/mol.107.036772
58. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013; 504:138-42; PMID:24185007; http://dx.doi.org/10.1038/nature12688
59. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24:1547-8; PMID:18467348; http://dx.doi.org/10.1093/bioinformatics/btn224
60. Baldi P, Long AD. A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics 2001; 17:509-19; PMID:11395427; http://dx.doi.org/10.1093/bioinformatics/17.6.509
61. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature medicine 2005; 11:77-84; PMID:15619633; http://dx.doi.org/10.1038/nm1161